Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic

Palliative Medicine

Volumn 20, Issue 3, 2006, Pages 215-216

  White, Clare ^a   McPherson, Alan ^a   McCann, Mary Ann ^a   Sadler, Aaroon ^a   Fyvie, Joan ^a  

^a Marie Curie Centre   (United Kingdom)

Author keywords

Anti emetic; Extrapyramidal; Haloperidol; Parkinsonism; Side effect

Indexed keywords

ANTIEMETIC AGENT; CYCLIZINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL;

AGED; ARTICLE; BONE METASTASIS; BRADYKINESIA; BREAST CARCINOMA; CANCER PALLIATIVE THERAPY; CASE REPORT; EXTRAPYRAMIDAL SYNDROME; FEEDING DISORDER; FEMALE; GAIT DISORDER; HUMAN; HYPERCALCEMIA; HYPERSALIVATION; MUSCLE RIGIDITY; NAUSEA AND VOMITING; PARKINSONISM; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; WHEELCHAIR;

AGED; ANTIEMETICS; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; NAUSEA; PARKINSONIAN DISORDERS; VOMITING;

EID: 33745036170     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216306pm1118cr     Document Type: Article

References (7)

1. Twycross R, Wilcock A. Symptom management in advanced cancer, third edition. Radcliffe Medical Press, 2001.
2. Simpson GM, Amuso D, Blair JH, et al. Phenothiazine-produced extrapyramidal system disturbance. Arch Gen Psychiatry 1964; 10: 199-208.
3. Buttner MD, Walder B, von Elm E, et al. Is low-dose haloperidol a useful antiemetic?: a meta-analysis of published and unpublished randomized trials. Anesthesiology 2004; 101: 1454-63.
4. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol an update. Clin Pharmacokinet 1999; 37: 435-56.
5. de Leon J, Diaz FJ, Wedlund P, et al. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol 2004; 24: 656-60.
6. Kornhuber J, Schultz A, Wiltfang J, et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999; 156: 885-90.
7. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med 2004; 18: 195-201.